Company news
Imagion Biosystems Ltd. (ASX:IBX) news
Every Imagion Biosystems Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Imagion Resumes MagSense® Nanoparticle Manufacturing Capabilities
September 14, 2026
IBX Phase 2 Clinical Trial Update
August 25, 2026
Appendix 4C and Quarterly Activities Report - June 2026
July 30, 2026
Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
June 25, 2026
IBX Secures Firm Commitments for $3.75m for Clinical Trial
June 24, 2026
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 2, 2026
Imagion Biosystems Receives IND Clearance from US FDA
June 1, 2026
Appendix 4C and Quarterly Activities Report - March 2026
April 23, 2026
FY25 Appendix 4E and Annual Report
February 27, 2026
Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
February 3, 2026
IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial
February 1, 2026
Appendix 4C and Quarterly Activities Report - December 2025
January 28, 2026
Mercer Convertible Securities Conversion and Amendment
January 7, 2026
Positive Final WSU Trial Results To Support IND Submission
December 1, 2025
Positive Results Received from WSU on MagSense Dosage
November 4, 2025
Appendix 4C and Quarterly Activities Report - September 2025
October 20, 2025
Imagion Biosystems HER2 Breast Cancer Program Update
October 6, 2025
Ph2 Manufacturing & Imaging Optimisation Activities Commence
September 7, 2025
Appendix 4D and Half-yearly Financial Report
August 27, 2025
IBX Secures Firm Commitments for A$3.5m Capital Raising
August 3, 2025
Trading Halt
July 30, 2025
Appendix 4C and Quarterly Activities Report - June 2025
July 28, 2025
Imagion MagSense Breast Cancer Program Phase 2 Trial Update
July 14, 2025
Imagion Receive Positive FDA Feedback for HER2 Phase 2 Trial
July 9, 2025
Appendix 4C and Quarterly Activities Report - March 2025
April 30, 2025
Appendix 4E and 2024 Financial Report
February 28, 2025
Imagion Initiates Manufacturing of Drug for Phase 2 Study
February 18, 2025
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2025
Successful Placement of A$3M
October 10, 2024
Response to ASX Price Query
September 30, 2024
Half Yearly Report and Accounts
August 30, 2024
Variation of Convertible Securities Agreement
July 17, 2024
Imagion appoints new Non-Executive Director
June 14, 2024
Reinstatement to Quotation
June 14, 2024
Prospectus - Convertible Notes
May 21, 2024
Suspension from Quotation
April 1, 2024
Appendix 4E and Preliminary Final Report
February 29, 2024
Imagion Announces CEO Departure
January 15, 2024
Imagion Announces Positive Results from Phase 1 Study
December 6, 2023
Phase 1 Study Closure and Preliminary Performance
October 17, 2023
Notice of Extraordinary General Meeting/Proxy Form
October 12, 2023
Imagion presents ovarian cancer data at AACR conference
October 8, 2023
2022 R&D Tax Refund
September 18, 2023
Appendix 4D
August 29, 2023
Half-Year Results Release
August 29, 2023
Non-renounceable Entitlement Offer Shortfall
July 14, 2023
Imagion to complete the MagSense HER2 Phase 1 Study
June 20, 2023
Imagion Announces New CEO
June 18, 2023
Results of Non-renounceable Entitlement Offer
April 18, 2023
Imagion Funding Update
March 6, 2023